Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2015-03-18 Capital/Financing Update
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 18, 2015, reporting the entry into a material definitive agreement involving a private placement of common stock and warrants. It details the securities purchase agreement, the private placement terms, and related registration rights. The content focuses on financing activities, including issuance of shares and warrants, proceeds, and use of funds. There are no financial statements or quarterly/yearly financial results presented, nor is it a report of management or audit. The primary subject is the company's capital raising transaction. Therefore, this filing fits the category of Capital/Financing Update (CAP). The document length (8160 characters) and detailed description of the financing transaction support this classification with high confidence.
2015-03-18 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-03-17 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 13, 2015. It announces a contemplated private placement of common stock and warrants, which is a financing activity. The document includes exhibits such as a press release, a selected financial data sheet, and an investor presentation related to the private placement. The main content is an update on financing activities rather than a full financial report or earnings release. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 3744 characters, which is consistent with a typical 8-K filing for such an event, not a full report or presentation itself.
2015-03-13 English
8-K
Investor Presentation Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce significant events. The key content is the attachment of an investor presentation dated March 2015, which the company states it may use in conversations with investors and analysts. The document itself is short (2413 characters) and primarily serves to file the investor presentation as an exhibit. There are no financial statements or detailed financial analysis within the text, only a reference to the presentation. According to the classification rules, an investor presentation attached to an 8-K and described as such should be classified as Investor Presentation (IP).
2015-03-03 English
Major Shareholding Notification 2015
Major Shareholding Notification
2015-02-13 English
SC 13D/A
Major Shareholding Notification
2015-02-05 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.